Product Description for SET / I2PP2A
Properties: Control Peptide
Properties for SET / I2PP2A
|Product Category||Control Peptides|
|Synonyms||I-2PP2A, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I|
|PDF datasheet||View Datasheet|
|Manufacturer||Acris Antibodies GmbH|
|Material safety datasheet||MSDS for Polyclonal Antibodies (de)|
Incubate antibody neat with at least a 50 fold stoichiometric excess of blocking peptide at 37°C for 20 minutes (molecular weights of peptide and antibody are ~2.5 kDa and ~160 kDa, respectively). Antibody can then be diluted to a concentration suitable for Western blot.
|Background||Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.|
|Storage||Store at -20°C.
Avoid repeated freezing and thawing.
Shelf life: one year from despatch.